03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase .
Item 1.01. Entry Into a Material Definitive Agreement.
On June 16, 2023, Iovance Biotherapeutics, Inc. entered into a
new Open Market Sale Agreement with Jefferies LLC with respect to an at the. | June 16, 2023
Form 10-Q FUELCELL ENERGY INC For: Apr 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
INFORMATION CONTAINED IN THIS CURRENT REPORT ON FORM 6-K On April 25, 2023, Arbe Robotics Ltd. entered into an Open Market Sale AgreementSM with Jefferies LLC with respect to. | April 25, 2023
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023